Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial

Lancet

Volumn 365, Issue 9463, 2005, Pages 947-954

  Rascol, O ^a   Brooks, D J ^b   Melamed, E ^c   Oertel, W ^d   Poewe, W ^e   Stocchi, F ^f   Tolosa, E ^g  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c TEL AVIV UNIVERSITY   (Israel)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF INNSBRUCK   (Austria)

^f IRCCS NEUROMED   (Italy)

^g UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PLACEBO; RASAGILINE; ANTIPARKINSON AGENT; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE; ENZYME INHIBITOR; INDAN DERIVATIVE; MONOAMINE OXIDASE INHIBITOR;

ADULT; AGED; ANXIETY; ARGENTINA; ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EUROPE; FEMALE; HALLUCINATION; HOSPITAL; HUMAN; HYPERKINESIA; INFORMED CONSENT; ISRAEL; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTPATIENT; PARALLEL DESIGN; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYNCOPE; TREATMENT OUTCOME; UNPLEASANT DREAM; VOMITING; XEROSTOMIA; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG COMBINATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; ENZYME INHIBITORS; HUMANS; INDANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 15844386001     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)71083-7     Document Type: Article

References (22)

1. CD Marsden Parkinson's disease Lancet 335 1990 948 952
2. Movement Disorder Society Task Force Management of Parkinson's disease: an evidence-based review Mov Disord 17 suppl 4 2002 S1 166
3. O Rascol, C Goetz, W Koller, W Poewe, C Sampaio Treatment interventions for Parkinson's disease: an evidence based assessment Lancet 359 2002 1589 1598
4. CE Clarke, JM Speller Pergolide for levodopa-induced complications in Parkinson's disease Cochrane Database Syst Rev 2 2004 CD00235
5. CE Clarke, JM Speller, JA Clarke Pramipexole for levodopa-induced complications in Parkinson's disease Cochrane Database Syst Rev 2 2004 CD002261
6. CE Clarke, KHO Deane Ropinirole for levodopa-induced complications in Parkinson's disease Cochrane Database Syst Rev 2 2004 CD001516
7. Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease. The TEMPO study Arch Neurol 59 2002 1937 1943
8. JM Rabey, I Sagi, M Huberman for the Rasagiline Study Group Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa Clin Neuropharmacol 23 2000 324 330
9. Parkinson Study Group Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients Ann Neurol 42 1997 747 755
10. UK Rinne, JP Larsen, Å Siden, J Worm-Petersen the Nomecomt Study Group Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations Neurology 51 1998 1309 1314
11. MM Hoehn, MD Yahr Parkinsonism: onset, progression, and mortality Neurology 17 1967 427 442
12. MF Folstein, SE Folstein, PR McHugh "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J Psychiat Res 12 1975 189 198
13. RA Hauser, J Friedlander, TA Zesiewicz A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia Clin Neuropharmacol 23 2000 75 81
14. National Institute for Mental Health 028 CGI. Clinical global impressions W Guy ECDEU assessment manual for psychopharmacology 1976 US Department of Health, Education, and Welfare Rockville, MD, USA 217 222
15. S Fahn, RL Elton UPDRS development committee Unified Parkinson's Disease Rating Scale S Fahn CD Marsden D Calne M Goldstein Recent developments in Parkinson's disease 1987 Macmillan Florham Park, NJ, USA 153 164
16. JW Langston, H Widner, CG Goetz Core Assessment Program for Intracerebral Transplantations (CAPIT) Mov Disord 7 1992 2 13
17. US Department of Health Education and Welfare Coding symbols for thesaurus of adverse drug reaction terms (COSTART) 1995 US Drug and Food Administration, Centre for Drug Evaluation and Research Rockville, MD, USA
18. AL Gould, WJ Shih Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance Commun Statist Theory Meth 21 1992 2833 2853
19. M Guttman the International Pramipexole-Bromocriptine Study Group Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease Neurology 49 1997 1060 1065
20. L Wermuth the Danish Pramipexole Study Group A double-blind placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease Eur J Neurol 5 1998 235 242
21. H Heikkinen, M Saraheimo, S Antila, P Ottoila, PJ Pentikäinen Pharmacokinetics of entacapone, a peripherally acting catechol-O- methyltransferase inhibitor, in man. A study using a stable isotope technique Eur J Clin Pharmacol 56 2001 821 826
22. O Rascol, P Payoux, F Ory, JJ Ferreira, C Brefel-Courbon, J-L Montastruc Limitations of current Parkinson's disease therapy Ann Neurol 53 suppl 3 2003 S3 S15